Please assess the completion status of the following clinical trial:

Trial Title: Human Milk Oligosaccharide (HMO) Supplementation in Colic Management

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Infants 2 weeks - 12 weeks of age at enrolment~2. Infants diagnosed with colic according to Rome IV criteria: Diagnostic criteria for research purposes (infant must meet all Rome IV criteria):~   1. An infant who is less than 5 months of age (in the current clinical trial, only infants 2 weeks to 8 weeks of age will be enrolled) when the symptoms start and stop~  2. Recurrent and prolonged periods of infant crying, fussing, or irritability reported by caregivers that occur without obvious cause and cannot be prevented or resolved by caregivers~  3. No evidence of infant failure to thrive, fever, or illness~  4. Excessive crying/fussiness for 3 or more hours per day during 3 or more days in the past 7 days as reported by parents to the clinician~  5. Total 24-hour crying plus fussing is 3 hours or more when measured by at least one prospectively kept 24-hour behavior diary. (The Structured Infant Crying and Fussing Diary will be dispensed at the screening visit (V0), completed for two 24-hour periods at H0 (days -3 to -1), and returned at V1 to be used as part of the diagnostic criteria for infantile colic.)~3. Term infants (≥ 37 weeks) generally healthy with normal birth weight (≥2.5kg) and singleton born~4. Predominantly formula fed\* (formula fed ≥ 80% of the time) for at least 7 days before randomization and the choice of formula feeding has been made by the parents before the beginning of the trial.~5. Infants who have been on the same formula for the past 5 days~6. Signed informed consent obtained for infant's and parents'/Legally Acceptable Representative (LAR) participation in the study~7. Parent/LAR of infant agrees not to enroll infant in another interventional clinical research study while participating in this study~8. Parent of the infant/LAR is willing and able to fulfill the requirements of the study protocol~9. Parent of infant can be contacted throughout the study~   * Predominantly formula feeding defined in the study means that the infant's predominant source of nourishment is formula. Specifically, infants are fed with formula for at least 80% of total milk feeds per day.~Exclusion criteria:~1. Presence of any congenital condition and/or previous or current illness/infection and (or) medication use that could interfere with the main study outcomes.~2. Clinical evidence of chronic illness or gastrointestinal disorders, major medical problems (e.g. ill, immunocompromised, major developmental or genetic abnormality).~3. Known cow's milk protein allergy, lactose intolerance, or galactosaemia; including presence of any allergic manifestations.~4. Received any special formula (e.g. lactose-free, hydrolyzed protein) within 5 days before randomization or switched formulas within 5 days before randomization.~5. Received any of the following products/medication within 5 days before randomization:~   * Antibiotics~  * Alginate~  * Prokinetics~  * Proton pump inhibitors~  * Simethicone~  * L. reuteri probiotic~  * Formula containing Human milk Oligosaccharides~6. Other infant(s) \<6months of age living in the same household.~7. Current participation in another interventional clinical trial.

- Gender: ALL
- Minimum Age: 2 Weeks
- Maximum Age: 12 Weeks
- Healthy Volunteers: f

Study Arms:
- Liquid oral supplement comprising HMO (Type: EXPERIMENTAL): 2 ampules/day for 21 days
- Placebo (Type: PLACEBO_COMPARATOR): 2 ampules/day for 21 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues